Omez D

Quick links to important sections

Omez D

Selected form

Treatment option: Reflux

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omez D

What is Omez D?

Omez D is a fixed-dose combination medication composed of two active pharmaceutical ingredients: omeprazole and domperidone. It is primarily utilized to manage gastrointestinal conditions characterized by excessive acid production and impaired gastric motility.

Composition and Mechanism of Action

The effectiveness of Omez D is derived from the synergistic action of its two primary components:

  • Omeprazole: This ingredient belongs to a class of drugs known as proton pump inhibitors (PPIs). It works by targeting the gastric proton pump (H^+/K^+-ATPase enzyme system) found in the parietal cells of the stomach lining. By inhibiting this system, it effectively reduces the secretion of hydrochloric acid.
  • Domperidone: This component is categorized as a dopamine antagonist with prokinetic properties. It acts on the upper digestive tract to increase the movements or contractions of the stomach and intestines. This action facilitates the faster passage of food through the stomach and helps prevent the backflow of stomach contents into the esophagus.

Clinical Applications

Omez D is commonly used for conditions where acid reduction and improved gastric emptying are both required. These typically include:

  • Gastroesophageal Reflux Disease (GERD): A condition where stomach acid frequently flows back into the tube connecting the mouth and stomach, causing irritation.
  • Functional Dyspepsia: A term for recurring signs and symptoms of indigestion that have no obvious cause, often involving bloating, fullness, and discomfort.
  • Peptic Ulcer Disease: Specifically in cases where associated symptoms like nausea or slow digestion are present.
  • Acid-related Gastritis: Inflammation of the stomach lining that is exacerbated by acid and associated with nausea.

Regulatory References

  1. U.S. National Library of Medicine (MedlinePlus)
  2. National Center for Biotechnology Information (NIH)

What side effects are possible with Omez D?

Possible Side Effects and Safety Information

This section outlines the adverse reactions and high-level safety constraints of the Omeprazole and Domperidone combination, as officially documented in government regulatory labeling. The safety profile is characterized by effects classified by frequency and System-Organ Class (SOC) for each active component.


Frequency-Classified Adverse Reactions

The following are classified according to official frequency standards:

  • Common Reactions (Omeprazole component): Includes headache, abdominal pain, constipation, diarrhea, flatulence, nausea, and vomiting. The Domperidone component commonly lists dry mouth.
  • Uncommon Reactions: May include dizziness, insomnia, skin rash, pruritus, and increases in liver enzymes.

Serious Adverse Reactions and Safety Constraints

Government regulatory sources document a risk of serious ventricular arrhythmias (including QTc prolongation and Torsade de Pointes) and sudden cardiac death associated with the Domperidone component. This risk is noted to be increased in older adults and is officially restricted in patients with pre-existing cardiac conditions or moderate to severe hepatic impairment.

For the Omeprazole component, rare but serious events include Acute Tubulointerstitial Nephritis (TIN) and Severe Cutaneous Adverse Reactions (SCARs). Additionally, official labeling notes that long-term, high-dose use may be associated with an increased risk of bone fracture (hip, wrist, or spine) and hypomagnesemia.

The official labeling also requires that the symptomatic response to Omeprazole should not preclude the need to exclude gastric malignancy.

Overdose and Emergency Response

A drug overdose is defined by regulatory authorities as consuming a dose substantially exceeding the normal therapeutic amount. Due to the dual composition of omeprazole and domperidone, the resulting overdose profile is complex. Seek emergency medical attention or contact a poison control center right away for any suspected overexposure.

Overdose manifestations are formally documented to include gastrointestinal symptoms like nausea, vomiting, and abdominal pain, along with central nervous system effects such as headache, confusion, and drowsiness. Overexposure to the domperidone component specifically carries the risk of neurological signs, including disorientation, agitation, and extrapyramidal reactions such as involuntary muscle movements or convulsions.

The official regulatory documentation highlights the potential for serious ventricular arrhythmias and QTc prolongation with domperidone overdose. Due to this documented cardiac risk, continuous ECG monitoring in a hospital setting is required. Individuals over the age of 60 or those taking doses over 30 mg of domperidone daily are noted to have a higher potential for serious cardiac effects. Management is strictly symptomatic and supportive treatment, as regulatory agencies state that no specific antidote is known for either component.

Therapeutic Uses of Omez D

Quick Facts

  • Condition Management: Approved for the management of Gastroesophageal Reflux Disease (GERD).
  • Symptom Relief: Helps to alleviate symptoms associated with acid-related digestive conditions, including heartburn and indigestion.
  • Related Uses: May be prescribed for the management of peptic ulcers and Zollinger-Ellison syndrome.

What Omez D Treats: Main Uses and Benefits

Omez D is a therapeutic option indicated for the management of several conditions related to the digestive system. Its primary role is to reduce excessive stomach acid production and support the normal movement of the stomach and intestines, which may help food pass more easily through the digestive tract.

This medication is frequently used in the treatment of Gastroesophageal Reflux Disease (GERD). For individuals with GERD, it may provide relief from acid-related symptoms such as persistent heartburn, acid reflux, and discomfort in the upper abdomen. By modulating acid levels, it helps prevent acid-related damage to the lining of the stomach and esophagus.

In addition to GERD, Omez D is beneficial in the management of peptic ulcer disease and conditions involving the overproduction of gastric acid, such as Zollinger-Ellison syndrome. The medication supports the healing of existing ulcers and helps reduce the likelihood of their recurrence, thereby improving overall gastrointestinal comfort and patient well-being.

Eligibility and Restrictions for Use

Who Can and Cannot Use Omez D?

Eligibility for Omez D (Omeprazole/Domperidone) is strictly defined by government regulatory agencies and based on the established risks associated with its two components.

Absolute Non-Eligibility (Contraindications)

Contraindicated Group Restriction Rationale (Official Labeling)
Cardiac Conditions Patients with known QTc prolongation, underlying heart diseases like congestive heart failure, or significant electrolyte disturbances (e.g., hypokalaemia) must not use this medicine.
Hepatic Impairment Contraindicated in patients with moderate or severe hepatic impairment (liver failure).
Gastrointestinal Risk Contraindicated in patients with conditions where gut motility stimulation is dangerous, such as gastrointestinal hemorrhage, obstruction, or perforation.
Lactation Contraindicated in breastfeeding mothers.

Age and Restricted Use

  • Adults (18 years and older): Generally eligible for use in labeled conditions, provided no absolute contraindications exist.
  • Pediatrics (lt 18 years): The combination is not recommended for use in children and adolescents, as safety and efficacy have not been formally established.
  • Older Adults (ge 60 years): Use requires special caution and careful assessment due to a documented higher risk of cardiac side effects, as noted in regulatory reviews.
  • Renal Impairment: Use is not recommended in patients with severe renal impairment.

Regulatory documentation defines who can use this combination medicine by imposing strong prohibitions on patients with cardiovascular or severe organ function issues, thereby confining eligibility to adults who are free of these specific high-risk conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Omez D based on the components omeprazole and domperidone, establishing specific prohibitions and use restrictions.

Contraindicated Combinations

Co-administration is strictly contraindicated with two main classes of medicines:

  • Potent CYP3A4 Inhibitors: Agents like oral Ketoconazole and Erythromycin are forbidden due to the potential for a marked increase in domperidone plasma concentrations, which elevates the risk of serious ventricular arrhythmias.
  • Medicines that Prolong the QTc Interval: Drugs with this known effect are contraindicated due to the increased risk of QTc prolongation and sudden cardiac death associated with the domperidone component.

Pharmacokinetic and Absorption Restrictions

Mechanism / Restriction Interacting Substances Regulatory Implication
CYP2C19 Inhibition Clopidogrel, Diazepam, Cilostazol, Tacrolimus Omeprazole reduces the exposure to the active metabolite of Clopidogrel and increases systemic exposure for agents like Cilostazol.
pH-Dependent Absorption Atazanavir, Rilpivirine, Ketoconazole Omeprazole's effect on gastric pH significantly reduces the plasma levels of certain antiretrovirals and antifungals, making combinations like Rilpivirine contraindicated.
CYP Induction Rifampin, St. John's Wort These substances are advised against as they may reduce omeprazole concentrations.

Special Interaction Conditions

  • Timing Separation: Antacids or other antisecretory agents must not be taken simultaneously with the domperidone component, as this lowers its oral bioavailability. A time separation is required by regulatory guidance.
  • Population Notes: The risk of serious ventricular arrhythmias is documented as higher in patients over 60 years old or at daily domperidone doses greater than 30 mg. Use is contraindicated in patients with moderate or severe hepatic impairment.

Mechanism of Action

This combination medication exerts its effect through two complementary and distinct pharmacodynamic mechanisms, addressing both the chemical and mechanical components of upper gastrointestinal regulation.


Irreversible Suppression of Gastric Acid Production

This component engages the final step of the gastric acid secretion pathway. The molecule is converted into an active form that creates a covalent, irreversible bond with the H^+/ K^+ ATPase enzyme system, or proton pump, within the parietal cells . The deactivation of this enzyme results in a significant and lasting reduction in the volume and acidity of hydrochloric acid output, independent of secretory stimuli.


Peripheral Modulation of Gastrointestinal Motility

This distinct mechanism involves the antagonism of peripheral Dopamine D2 receptors found in the enteric nervous system and the chemoreceptor trigger zone (CTZ). Blocking these receptors leads to increased acetylcholine activity, which enhances smooth muscle contractility. The resulting physiological effects include an increase in the resting pressure of the lower esophageal sphincter (LES) and an acceleration of gastric emptying, contributing to a mechanical resistance against gastric reflux and regulating neuro-emetic signaling.

Dosage and Administration Information

How Omez D is Used: Administration Guidelines

Omez D (Omeprazole and Domperidone) is a fixed-dose combination medication for oral use only, with administration rules defined to ensure proper delivery of both active ingredients.

Standard Dosing Protocol for Adults

The standard adult regimen is typically one unit dose of the combination, such as Omeprazole 20 mg and Domperidone 30 mg, taken once daily. The treatment course is commonly defined as short-term, often for a period of up to eight weeks for acute symptom management.

Administration Constraint Standard Rule
Route of Administration Must be taken orally (capsule or tablet).
Timing Relative to Food Must be taken before a meal, specifically on an empty stomach (e.g., 30 minutes before breakfast).
Form Integrity The capsule or tablet must be swallowed whole; it must not be crushed, chewed, or opened.

Special Population Rules

Prescribing information addresses dosage considerations for the individual components in certain patient groups:

  • Hepatic Impairment: Dose adjustment, which may involve a reduction of the omeprazole component (e.g., to 10 mg or 20 mg daily), may be required for patients with impaired liver function.
  • Renal Impairment: Dose adjustment is generally not necessary for the omeprazole component.

Following these precise procedural steps ensures the standardized use of the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Omez D

This section describes the types of research conducted using this combination medication and summarizes the patterns that studies have reported, while clarifying what information is currently limited or unavailable.


Evidence for use in Gastroesophageal Reflux Disease (GERD)

The use of this combination therapy was studied for managing symptoms of GERD. Research has mainly involved short-term randomized controlled trials (RCTs) that typically included adults. These studies monitored changes in symptom severity, frequency, and measurements of change in the esophageal lining over defined time intervals. Findings describe patterns observed in the studies where participants reported measurements of change in outcomes related to physical discomfort, such as heartburn, and reported an evolution or shift in their reflux symptom severity during the short study period. However, certainty remains low for many aspects of this use, as evidence is primarily limited to short-term follow-up durations.


Evidence for use in Peptic Ulcer Diseases (PUD)

The combination was evaluated in studies examining patient-reported experiences related to conditions involving changes in the presentation of stomach and duodenal ulcers. The research focused on outcomes related to changes in the presentation of ulcers and patient-reported outcomes describing perceived discomfort. Research highlights measurements recorded during the study period, with some findings indicating patterns related to the reported experiences of symptoms like stomach pain. The available data are still emerging for this specific combination in PUD, and the data are heterogenous across studies.


Long-Term Studies and Follow-Up

Studies monitored participants for relatively short durations, and consequently, long-term effects are not fully established for this combination. There is limited information for long-term outcomes regarding the continuous use of the therapy. The evidence describes group patterns related to immediate or short-term changes, but the durability of the reported responses over an extended period is not well characterized.


What is Still Uncertain About Omez D

The primary uncertainties revolve around the modest sample sizes used in many trials, which suggest caution when considering the broad applicability of the reported findings. The available data are heterogenous across studies, and findings were mixed or inconsistent across different populations and study designs. A key limitation is the absence of comprehensive data on long-term safety and whether the combination was associated with sustained changes in outcomes. Research is ongoing, and existing studies highlight significant gaps where more study is needed.

Key Studies & References

  1. Gastroesophageal Reflux Disease (GERD) - StatPearls (Source for clinical context and standard of care)
  2. A Comprehensive Review on Omeprazole: Pharmacological Effects and Its Adverse Effects (Source for long-term and safety context)

Frequently Asked Questions (FAQ)

Common questions about Omez D (FAQ)


Q: Is Omez D the same as just taking Omeprazole?

No, official product information describes Omez D as a fixed-dose combination medication. It contains two distinct active ingredients: Omeprazole, which is a proton pump inhibitor used to reduce stomach acid, and Domperidone, which is a prokinetic agent that helps improve movement in the digestive tract. Taking only Omeprazole would not provide the intended combined dual-action effect.


Q: How quickly does Omez D start working?

Clinical information indicates that the Omeprazole component is not intended for instant relief and is not a quick-acting antacid. For the full acid-reducing effect to be achieved, this component may require between one to four days of regular daily use. The Domperidone component, which affects motility, may begin its action within a different timeframe than the acid-reducing component.


Q: How long does the effect of one dose of Omez D last?

The acid-suppressing action of the Omeprazole component is described in regulatory documents as long-lasting. This lasting reduction in acid secretion continues for an extended period, reflecting the drug's mechanism of action on the proton pump.


Q: Is Omez D intended for short-term or long-term use?

Regulatory documents describe treatment with this medication as typically being a short-term course. Use of the Omeprazole component is often limited to a period of up to eight weeks for the healing of certain conditions. The treatment duration is determined by the prescribing physician.


Q: Can Omez D be taken 'as needed'?

The Omeprazole component, which is the acid-suppressing drug, is a proton pump inhibitor. This class of medicine is generally not intended for use 'as needed' (PRN). For its full therapeutic effect to be achieved, official guidance recommends it be taken as a consistent, regular daily course.


Q: Can Omez D cause drowsiness or affect driving?

Yes, official labeling lists side effects such as drowsiness and dizziness or giddiness (impaired balance). Due to the potential for these central nervous system effects, patients are generally advised to use caution and avoid activities like driving or operating heavy machinery if they experience them.


Q: Are there specific vitamins or minerals that Omez D can affect?

Yes, official warnings regarding the Omeprazole component indicate that long-term daily use (e.g., longer than three years) may potentially lead to a Vitamin B-12 deficiency. The medicine is also associated with an increased risk of hypomagnesemia (low magnesium levels) in some patients.


Q: Is it common to feel nauseous after starting Omez D?

Nausea is classified in official documents as a common adverse reaction associated with the Omeprazole component of the medication. The initial onset is not specifically documented, but effects classified as common are frequently reported.


Q: Is Omez D safe for older adults (seniors)?

Official information states that use in older adults (60 years and over) requires special caution and careful assessment. This is due to a documented higher risk of specific cardiac side effects associated with the Domperidone component in this age group.


Q: Is there a different version of Omez D for children?

The combination medication is not recommended for use in children and adolescents who are under 18 years of age. Regulatory agencies state that the safety and efficacy of the combination have not been formally established in this patient population.


Q: What should I do if I miss a scheduled dose of Omez D?

Regulatory instructions address a missed dose by advising that it may be taken as soon as it is remembered, provided the next dose is not too close. Official guidelines caution against taking two doses at the same time to compensate for a missed dose.


Q: Is Omez D known to cause dry mouth?

Yes, official safety labeling confirms that dry mouth is classified as a common adverse reaction associated with the Domperidone component of the medicine.


Q: Is there a risk of withdrawal symptoms when stopping Omez D?

Studies on the Omeprazole component indicate that discontinuing long-term use may potentially lead to an effect known as rebound acid hypersecretion. This phenomenon can cause a return or worsening of the original reflux symptoms.


Q: Is the use of Omez D supported by long-term research?

The available research is primarily focused on short-term randomized controlled trials conducted over a limited duration. Regulatory summaries state that, consequently, the long-term effects are not fully established and data on long-term safety are limited for this combination.


Q: Does Omez D affect the body's natural gut bacteria?

PPI therapy, such as the Omeprazole component, is associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), which is noted in warnings. This involves changes in the bacterial environment in the colon.


Q: Are there any specific foods to avoid while on Omez D?

Official guidance requires the medication to be taken on an empty stomach (before a meal). The medicine has no known direct adverse interaction with food, but acidic, fatty, or spicy foods are commonly known to aggravate the underlying GERD or dyspepsia symptoms.


Q: Is it true that Omez D can affect how other medications are absorbed?

Yes, this is noted in official documentation. The Omeprazole component works by significantly reducing stomach acid, which increases gastric pH. This change in acidity can lead to a reduced absorption and lower plasma levels of other medications that require a certain acidic environment to be properly absorbed by the body.


Q: Is Omez D used to treat H. pylori infection?

The Omeprazole component, which is a powerful acid suppressor, is commonly used as part of a multi-drug regimen. It is typically combined with antibiotics (known as triple therapy) to manage ulcers associated with the H. pylori bacterial infection.


Q: What are the signs that Omez D is working effectively?

Effectiveness is generally indicated by a reduction in symptoms, according to clinical study summaries. This includes decreased frequency and severity of heartburn and acid reflux, along with an improvement in discomfort related to poor digestive tract movement.


Q: Can Omez D be used for simple indigestion?

The medicine is officially indicated for dyspepsia (a term used for indigestion) when it is related to conditions like gastroparesis or gastroesophageal reflux disease (GERD). Use for general, non-specific indigestion should be determined by a healthcare provider.


Q: Can Omez D cause sleep disturbance or insomnia?

Yes, official safety labeling documents that insomnia (difficulty falling or staying asleep, or sleep disturbance) is classified as an uncommon adverse reaction associated with the medication.


Q: What is the significance of the coating on the Omez D capsule?

The capsule is often manufactured as an enteric-coated or delayed-release formulation. This special coating is required to ensure that the acid-sensitive Omeprazole component is protected from being destroyed by stomach acid before it reaches its intended absorption site in the intestine.


Q: Why do some people experience dizziness while taking Omez D?

Dizziness is listed as an uncommon adverse effect. This may be due to the Domperidone component, which is a dopamine receptor antagonist that can produce various central and peripheral nervous system effects in some individuals.

How should Omez D be stored and disposed of?

How to Store and Dispose of Omez D?

The storage and disposal of this medicine must follow official regulatory guidelines to maintain stability and ensure safety.

Storage Requirements

Temperature and Protection: Store Omez D at a controlled room temperature, generally 20 C to 25 C, and do not store above 25 C. The product must be protected from light and moisture [1, 2].

Packaging and Child Safety: The medicine should be kept in its original container, which must remain tightly closed. It is mandatory to keep the product out of the sight and reach of children [1, 2].

Stability: For bottles, discard the remaining product 100 days after first opening [2].

Disposal Instructions

Official Guidance: Unused or expired Omez D must be disposed of in accordance with local requirements. The medicine must not be discarded via household wastewater or standard trash unless specifically authorized by local regulations [2].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omez D found in:

A-Z Index: